Status and phase
Conditions
Treatments
About
This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.
Full description
This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42 with escalated doses in the treatment of patients with advanced/metastatic solid tumors. In this study, a 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX42 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX42.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
42 participants in 1 patient group
Loading...
Central trial contact
Yilong Wu, Dr.; Huajun Chen, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal